Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
E.L. Mazzaferri, R.T. Kloos.
Current approaches to primary therapy for papillary and follicular thyroid cancer.
J Clin Endocrinol Metab, 86 (2001), pp. 1447-1463
[2.]
M. Schlumberger, E. Baudin.
Serum thyroglobulin determination in the follow-up of patients with differenciated thyroid carcinoma.
Eur J Endocrinol, 138 (1998), pp. 249-252
[3.]
K.H. Dow, B. Ferrell, C. Anello.
Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.
Thyroid, 7 (1997), pp. 613-619
[4.]
T.F. Nijhuis, W. Van Weperen, J.M.H. De Klerk.
Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer.
Tijdschr Nucl Geneeskd, 21 (1999), pp. 98-100
[5.]
M.J. Schlumberger.
Papillary and follicular thyroid carcinoma.
N Engl J Med, 338 (1998), pp. 297-306
[6.]
L. Ramírez, L.E. Braverman, B. White, C.H. Emerson.
Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.
J Clin Endocrinol Metab, 82 (1997), pp. 2836-2839
[7.]
C.A. Meier, L.E. Braverman, S.A. Ebner, I. Veronikis, G.H. Daniels, D.S. Ross, et al.
Diagnostic use of recombinant human thryrotropin in patients with thyroid carcinoma (Phase I/II study).
J Clin Endocrinol Metab, 78 (1994), pp. 188-196
[8.]
P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri, F. Brucker-Davis, D.S. Cooper, J.R. Garber, et al.
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
N Engl J Med, 337 (1997), pp. 888-896
[9.]
B.R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P.W. Ladenson, S.I. Sherman, et al.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
J Clin Endocrinol Metab, 84 (1999), pp. 3877-3885
[10.]
G. Mariani, M. Ferdeghini, C. Augeri, G. Villa, G.Z. Taddei, G. Scopinaro, et al.
Clinical experience with recombinont human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer.
Cancer Biother Radiopharm, 15 (2000), pp. 211-217
[11.]
J.M. Durski, R.J. Weigel, I.R. McDougall.
Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroide cancer.
Nucl Med Commun, 21 (2000), pp. 521-528
[12.]
R.J. Robbins, R.M. Tuttle, R.N. Sharaf, S.M. Larson, H.K. Robbins, R.A. Ghossein, et al.
Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 86 (2001), pp. 619-625
[13.]
G. Vitale, A. Lupoli Gelsy, A. Ciccarelli, F. Fonderico, M. Klain, G. Squame, et al.
The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.
Clin Endocrinol, 56 (2002), pp. 247-252
[14.]
F. Pacini, E. Molinaro, F. Lippi, M.G. Castagna, L. Agate, C. Ceccarelli, et al.
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 86 (2001), pp. 5686-5690
[15.]
E.L. Mazzaferri, R.T. Kloos.
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?.
J Clin Endocrinol Metab, 87 (2002), pp. 1490-1498
[16.]
M. Luster, M. Lassmann, H. Haescheid, U. Michalowski, C. Incerti, C. Reiners.
Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 85 (2000), pp. 3640-3645
[17.]
G. Berg, G. Lindstedt, M. Suurküla, S. Jansson.
Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
J Endocrinol Invest, 25 (2002), pp. 44-52
[18.]
F. Lippi, M. Capezzone, F. Angelini, D. Taddei, E. Molinbaro, A. Pinchera, et al.
Radioiodine treatment of metastatic differentiated thyroid cancer on L-thyroxine using recombinant TSH.
Eur J Endocrinol, 144 (2001), pp. 5-11
[19.]
M. Braga, M.D. Ringel, D.S. Cooper.
Clinical case seminar. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration.
J Clin Endocrinol Metab, 86 (2001), pp. 5148-5151
[20.]
D.A. Huysmans, W.A. Nieuwlaat, R.J. Erdtsieck, A.P. Schellekens, J.W. Bus, B. Bravenboer, et al.
Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxic nodular goiter.
J Clin Endocrinol Metab, 85 (2000), pp. 3592-3596
[21.]
W.A. Nieuwlaat, A.R. Hermus, F. Sirvo-Prndelj, F.H. Corstens, D.A. Huysmans.
Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters.
J Clin Endocrinol Metab, (2001),
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición